SCOTUS agrees to hear Amgen revival bid

The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ invaded jury’s role in Repatha case, says Amgen

25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

Big Pharma

SCOTUS rejects BMS vs Gilead patent clash

10 November 2022 Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.

More on this story

Americas

Fed Circ invaded jury’s role in Repatha case, says Amgen

25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

Big Pharma

SCOTUS rejects BMS vs Gilead patent clash

More on this story

Americas

Fed Circ invaded jury’s role in Repatha case, says Amgen

25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

Big Pharma

SCOTUS rejects BMS vs Gilead patent clash